David Kandzari reviews the Spyral-HTN On study results for control of hypertension using renal denervation

SPYRAL HTN-ON MED confirmed RDN’s blood pressure lowering effect, in patients prescribed BP medications, at 6-months¹

• 24-hour systolic ambulatory blood pressure (ABPM) decreased 9.0 mmHg in RDN patients (P<0.0001)
• Office systolic blood pressure (OSBP) decreased 9.4 mmHg in RDN patients (P<0.0001)
• RDN is always on and provides 24-hr blood pressure lowering, including  during “high-risk” periods^2,3,4
• RDN procedures with the Symplicity SpyralTM system continued to be safe, despite a more rigorous approach¹ Zero major adverse events at 6-months
• Ablations were performed in the renal branch and accessory arteries, as well as main renal artery
• In previous research, BP reductions of the magnitude reported in SPYRAL HTN-ON MED have been associated with a >20% relative risk reduction of cardiovascular events⁵
• The SPYRAL HTN Global Clinical Program continues with the ongoing OFF MED pivotal trial
   

Footnotes/References:
¹Kandzari et al, PCR 2018
²The HTN-ON med 24-hr data showed that BP was reduced throughout the day and night at a 6-month endpoint
³Amodeo C, Blood Pressure Monit, 2014
⁴Boggia J, The Lancet, 2007
⁵Ettehad D et al.,  The Lancet, 2016